Dr Abiola Falilat Ibraheem is a medical oncologist at University of Illinois (UIC) dedicated to ensuring Sub-Saharan African countries is a hub for globalized biomarker-driven innovative therapeutic cancer clinical trials. Currently, she serves as the Director of the Global Oncology Program at UIC , where her work is centered on addressing disparities in cancer clinical trials within black communities in the United States and globally.
She also holds a pivotal role as a liaison between the American Society of Clinical Oncology (ASCO) and the newly established Sub-Saharan African Council. In addition, she is the chair of the diversity committee at Eli Lilly where her work is centered on ensuring representation of under-represented minorities in breast cancer trials.
Dr. Ibraheem began her career in Nigeria, where she received her medical education and worked for almost a decade as a medical officer in all the healthcare tiers within the country. Her invaluable experience in her home country laid the groundwork for her international journey.
Her internal medicine residency training was at Morehouse School of Medicine and at University of Chicago she trained as a medical oncologist and medical ethicist. She underwent an abbreviated physician program at Abbvie pharmaceuticals where she had first-hand experience on globalization of cancer clinical trials from Big Pharma and CROs perspective.
She is a past recipient of the African Cancer Leadership Institute (ACLI) and has been involved in multiple programs centered on clinical trial training of African investigators. She is currently an investigator on multiple ongoing globalized breast cancer trials.
